ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. ABBV
4. MU
5. META
6. SPY
7. ACN
8. BLZE
9. IBM
10. NKE

Go back to ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT

TD Cowen Reiterates Hold Rating on Sarepta Therapeutics (SRPT)

July 21, 2025 6:55 AM EDT

TD Cowen analyst Ritu Baral reiterated a Hold rating and $28.00 price target on Sarepta Therapeutics (NASDAQ: SRPT)

The analyst comments "Lack of proactive disclosure in recent rh74 GTx-related death undermines credibility with investors. Last week, at the start of the International LGMD Conference (Orlando), unsubstantiated media reports disclosed a 51 yr old pt in the Ph1/2 trial of rh74-based GTx SRP-9004 (for LGMD Type 2D) died 11 wks post-Tx... More

BofA Securities Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)

July 21, 2025 6:03 AM EDT

BofA Securities analyst Tazeen Ahmad reiterated a Neutral rating and $20.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).

The analyst comments "On Friday night, Sarepta (SRPT) reported that the company received an informal request from the Food and Drug Administration (FDA) to voluntarily halt all shipments of Elevidys. The company announced they plan... More